306:
Clonal TCR gene rearrangements for the γ and δ chains are typically found. The most frequent chromosomal abnormality is the inversion of chromosome 14, specifically inv 14(q11;q32). This is found in 80% of cases, while 10% of cases show a reciprocal translocation of
360:
that attacks white blood cells, has been used in treatment with greater success than previous options. In one study of previously treated people with T-PLL, people who had a complete response to alemtuzumab survived a median of 16 months after treatment.
1789:
333:
T-cell prolymphocytic leukemia is difficult to treat, and it does not respond to most available chemotherapeutic drugs. Many different treatments have been attempted, with limited success in certain patients:
557:
Brito-Babapulle V, Catovsky D (1991). "Inversions and tandem translocations involving chromosome 14q11 and 14q32 in T-prolymphocytic leukemia and T-cell leukemias in patients with ataxia telangiectasia".
1533:
628:
Sorour A, Brito-Babapulle V, Smedley D, Yuille M, Catovsky D (2000). "Unusual breakpoint distribution of 8p abnormalities in T-prolymphocytic leukemia: a study with YACS mapping to 8p11-p12".
1087:
593:
Maljaei SH, Brito-Babapulle V, Hiorns LR, Catovsky D (1998). "Abnormalities of chromosomes 8, 11, 14, and X in T-prolymphocytic leukemia studied by fluorescence in situ hybridization".
1204:
824:
1794:
105:
involvement. T-PLL is a very rare leukemia, primarily affecting adults over the age of 30. It represents 2% of all small lymphocytic leukemias in adults. Other names include
1603:
1817:
451:
380:, the median survival time was 7.5 months after diagnosis. More recently, some patients have survived five years and more, although the median survival is still low.
376:
T-PLL is an extremely rare aggressive disease, and patients are not expected to live normal lifespans. Before the recent introduction of better treatments, such as
1169:
1559:
898:
1249:
1762:
1801:
1347:
1092:
1226:
1327:
1125:
424:
Elaine Sarkin Jaffe, Nancy Lee Harris, World Health
Organization, International Agency for Research on Cancer, Harald Stein, J.W. Vardiman (2001).
1751:
1425:
979:
1598:
1417:
968:
388:
About four men are diagnosed with this disease for every three women. Despite its overall rarity, it is also the most common type of mature
298:- is present in 60% of cases, the CD4+/CD8+ immunophenotype is present in 25%, and the CD4-/CD8+ immunophenotype is present in 15% of cases.
1746:
1858:
1702:
1322:
1120:
1004:
219:
are usually round to oval in shape, with occasional patients having cells with a more irregular nuclear outline that is similar to the
1593:
40:
891:
435:
1554:
514:
Matutes E, Garcia
Talavera J, O'Brien M, Catovsky D (September 1986). "The morphological spectrum of T-prolymphocytic leukaemia".
227:. A small cell variant comprises 20% of all T-PLL cases, and the Sézary cell-like (cerebriform) variant is seen in 5% of cases.
1784:
1776:
1635:
1513:
1452:
1332:
1273:
1110:
1036:
1832:
1742:
1692:
1588:
1317:
1101:
1724:
1630:
1613:
1421:
975:
884:
1665:
1538:
1244:
1580:
1468:
1309:
1231:
365:
230:
Marrow involvement is typically diffuse with morphology similar to what is observed in peripheral blood. In the
1670:
1498:
835:
1136:
124:
People affected by T-cell prolymphocytic leukemia typically have systemic disease at presentation, including
1687:
1238:
1564:
1543:
1457:
864:
250:. Skin infiltrates are seen in 20% of patients, and the infiltrates are usually dense and confined to the
675:
1696:
1286:
1180:
343:
1259:
1082:
1493:
1105:
1016:
1293:
1077:
1047:
357:
347:
1757:
705:
539:
445:
220:
125:
224:
1837:
1507:
1488:
1477:
1267:
1157:
1072:
787:
746:
697:
645:
610:
575:
531:
493:
431:
54:
135:
Due to the systemic nature of this disease, leukemic cells can be found in peripheral blood,
1607:
1386:
1254:
1153:
876:
777:
736:
724:
687:
637:
602:
567:
523:
483:
335:
275:
160:
1380:
1375:
1184:
1068:
934:
929:
263:
129:
17:
1827:
829:
527:
318:
are seen approximately 75% of patients, including idic (8p11), t(8;8)(p11-12;q12), and
641:
606:
1852:
1734:
1433:
1342:
1298:
1115:
989:
571:
430:. World Health Organization Classification of Tumors. Vol. 3. Lyon: IARC Press.
308:
47:
709:
543:
1337:
999:
488:
471:
339:
315:
216:
183:
It is postulated that the originating cell line for this disease is a mature (post-
172:
168:
764:
Valbuena JR, Herling M, Admirand JH, Padula A, Jones D, Medeiros LJ (March 2005).
840:
425:
1011:
782:
377:
353:
201:
140:
136:
90:
86:
741:
330:
Most patients with T-cell prolymphocytic leukemia require immediate treatment.
907:
267:
247:
243:
239:
209:
59:
765:
692:
319:
212:
791:
750:
701:
649:
472:"Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia"
39:
816:
614:
579:
535:
497:
1822:
1650:
1361:
924:
911:
859:
235:
205:
78:
63:
427:
Pathology and genetics of tumours of haematopoietic and lymphoid tissues
676:"High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H"
155:. A high lymphocyte count (> 100 x 10/L) along with low amounts of
1370:
389:
251:
231:
184:
164:
156:
144:
98:
75:
1193:
1058:
1042:
148:
94:
82:
364:
Some patients who successfully respond to treatment also undergo
1656:
1550:
1529:
1447:
1189:
1164:
1144:
1140:
1027:
945:
940:
287:
152:
102:
880:
766:"T-cell prolymphocytic leukemia involving extramedullary sites"
470:
Matutes E, Brito-Babapulle V, Swansbury J, et al. (1991).
1396:
1391:
1281:
674:
Dearden CE, Matutes E, Cazin B, et al. (September 2001).
295:
291:
283:
279:
271:
1534:
Non-mycosis fungoides CD30− cutaneous large T-cell lymphoma
200:
In the peripheral blood, T-PLL consists of medium-sized
348:
cyclophosphamide, doxorubicin, vincristine, prednisone
115:
T-prolymphocytic leukemia/T-cell lymphocytic leukemia.
806:
1810:
1775:
1733:
1715:
1679:
1649:
1622:
1577:
1522:
1476:
1467:
1407:
1369:
1360:
1308:
1218:
1179:
1135:
1057:
1026:
988:
967:
956:
923:
850:
810:
53:
32:
1604:Peripheral T-cell lymphoma not otherwise specified
1426:Precursor T acute lymphoblastic leukemia/lymphoma
980:Precursor B acute lymphoblastic leukemia/lymphoma
270:cells are typically positive for pan-T antigens
266:of a mature (post-thymic) T-lymphocyte, and the
1170:Nodular lymphocyte predominant Hodgkin lymphoma
669:
667:
665:
663:
661:
659:
81:with aggressive behavior and predilection for
1560:Secondary cutaneous CD30+ large-cell lymphoma
892:
246:involvement is typically diffuse through the
8:
1250:Post-transplant lymphoproliferative disorder
1205:immunoproliferative immunoglobulin disorders
450:: CS1 maint: multiple names: authors list (
1763:Diffuse infiltrative lymphocytosis syndrome
1802:Jessner lymphocytic infiltrate of the skin
1473:
1404:
1366:
1348:Primary cutaneous follicle center lymphoma
1093:Primary cutaneous follicle center lymphoma
964:
953:
920:
899:
885:
877:
807:
215:with occasional blebs or projections. The
38:
29:
781:
740:
691:
487:
1328:Primary cutaneous marginal zone lymphoma
1126:Primary cutaneous marginal zone lymphoma
350:(CHOP), etoposide, bleomycin (VAPEC-B).
338:(pentostatin, fludarabine, cladribine),
234:, the leukemic cell infiltrate both the
1790:with bandlike and perivascular patterns
1752:Autoimmune lymphoproliferative syndrome
401:
1599:Enteropathy-associated T-cell lymphoma
509:
507:
465:
463:
461:
443:
419:
417:
415:
413:
411:
409:
407:
405:
72:T-cell-prolymphocytic leukemia (T-PLL)
7:
1747:X-linked lymphoproliferative disease
1703:Large granular lymphocytic leukemia
1323:Intravascular large B-cell lymphoma
342:, and various forms of combination
167:serologies are negative, and serum
126:enlargement of the liver and spleen
107:T-cell chronic lymphocytic leukemia
528:10.1111/j.1365-2141.1986.tb07579.x
163:in the blood are common findings.
25:
171:are within normal limits with no
725:"T-cell prolymphocytic leukemia"
254:and around the skin appendages.
111:"knobby" type of T-cell leukemia
1555:CD30+ cutaneous T-cell lymphoma
1785:Cutaneous lymphoid hyperplasia
1777:Cutaneous lymphoid hyperplasia
1636:Adult T-cell leukemia/lymphoma
1514:Adult T-cell leukemia/lymphoma
1453:Anaplastic large-cell lymphoma
1333:Primary cutaneous immunocytoma
1274:Splenic marginal zone lymphoma
489:10.1182/blood.V78.12.3269.3269
130:enlargement of the lymph nodes
33:T-cell-prolymphocytic leukemia
1:
1833:Lymphoproliferative disorders
1743:Lymphoproliferative disorders
1693:Extranodal NK-T-cell lymphoma
1565:Lymphomatoid papulosis type A
1544:Lymphomatoid papulosis type B
1458:Lymphomatoid papulosis type A
1318:Diffuse large B-cell lymphoma
642:10.1016/S0165-4608(00)00239-9
607:10.1016/S0165-4608(97)00410-X
368:to consolidate the response.
1725:Acute biphenotypic leukaemia
1614:Subcutaneous T-cell lymphoma
572:10.1016/0165-4608(91)90228-M
1666:Aggressive NK-cell leukemia
1539:Pleomorphic T-cell lymphoma
1245:Lymphomatoid granulomatosis
783:10.1309/93P4-2RNG-5XBG-3KBE
1875:
1859:Acute lymphocytic leukemia
742:10.1177/107327489800500102
919:
366:stem cell transplantation
221:cerebriform nuclear shape
46:
37:
18:Leukemia, T-Cell, chronic
1818:Hematological malignancy
1671:Blastic NK cell lymphoma
1499:Granulomatous slack skin
1255:Classic Hodgkin lymphoma
1154:Classic Hodgkin lymphoma
723:Matutes Estella (1998).
693:10.1182/blood.V98.6.1721
356:(Campath), an anti-CD52
132:, and skin infiltrates.
630:Cancer Genet. Cytogenet
595:Cancer Genet. Cytogenet
560:Cancer Genet. Cytogenet
314:Also, abnormalities of
290:. The immunophenotype
1697:Angiocentric lymphoma
1287:AIDS-related lymphoma
1111:Splenic marginal zone
344:chemotherapy regimens
311:(t(14;14)(q11;q32)).
1795:with nodular pattern
1494:Pagetoid reticulosis
1106:marginal zone B-cell
1294:Helicobacter pylori
1121:Nodal marginal zone
1048:Hairy cell leukemia
914:and related disease
770:Am. J. Clin. Pathol
358:monoclonal antibody
1838:Lymphoid leukemias
1758:Leukemoid reaction
1594:Angioimmunoblastic
1260:Burkitt's lymphoma
851:External resources
120:Signs and symptoms
1846:
1845:
1771:
1770:
1711:
1710:
1645:
1644:
1573:
1572:
1489:Mycosis fungoides
1356:
1355:
1214:
1213:
1158:Nodular sclerosis
1073:follicular B cell
874:
873:
282:and negative for
69:
68:
27:Medical condition
16:(Redirected from
1866:
1608:Lennert lymphoma
1474:
1405:
1367:
1232:Primary effusion
965:
954:
921:
901:
894:
887:
878:
808:
796:
795:
785:
761:
755:
754:
744:
720:
714:
713:
695:
671:
654:
653:
625:
619:
618:
590:
584:
583:
554:
548:
547:
511:
502:
501:
491:
467:
456:
455:
449:
441:
421:
336:purine analogues
302:Genetic findings
42:
30:
21:
1874:
1873:
1869:
1868:
1867:
1865:
1864:
1863:
1849:
1848:
1847:
1842:
1806:
1767:
1729:
1717:
1707:
1675:
1654:
1641:
1618:
1579:
1569:
1518:
1463:
1411:
1409:
1384:
1379:
1373:
1352:
1304:
1210:
1187:
1175:
1131:
1069:germinal center
1053:
1022:
984:
960:
958:
938:
933:
927:
915:
905:
875:
870:
869:
846:
845:
819:
805:
800:
799:
763:
762:
758:
722:
721:
717:
673:
672:
657:
627:
626:
622:
592:
591:
587:
556:
555:
551:
516:Br. J. Haematol
513:
512:
505:
482:(12): 3269–74.
469:
468:
459:
442:
438:
423:
422:
403:
398:
386:
374:
328:
304:
264:immunophenotype
260:
258:Immunophenotype
225:Sézary syndrome
198:
193:
181:
157:red blood cells
122:
28:
23:
22:
15:
12:
11:
5:
1872:
1870:
1862:
1861:
1851:
1850:
1844:
1843:
1841:
1840:
1835:
1830:
1828:Leukemia cutis
1825:
1820:
1814:
1812:
1808:
1807:
1805:
1804:
1799:
1798:
1797:
1792:
1781:
1779:
1773:
1772:
1769:
1768:
1766:
1765:
1760:
1755:
1749:
1739:
1737:
1731:
1730:
1728:
1727:
1721:
1719:
1713:
1712:
1709:
1708:
1706:
1705:
1700:
1683:
1681:
1677:
1676:
1674:
1673:
1668:
1662:
1660:
1647:
1646:
1643:
1642:
1640:
1639:
1626:
1624:
1620:
1619:
1617:
1616:
1611:
1601:
1596:
1591:
1585:
1583:
1575:
1574:
1571:
1570:
1568:
1567:
1562:
1557:
1547:
1546:
1541:
1536:
1526:
1524:
1520:
1519:
1517:
1516:
1508:Sézary disease
1502:
1501:
1496:
1491:
1482:
1480:
1471:
1465:
1464:
1462:
1461:
1455:
1443:
1442:
1439:Prolymphocytic
1429:
1415:
1413:
1402:
1401:
1400:
1394:
1364:
1358:
1357:
1354:
1353:
1351:
1350:
1345:
1340:
1335:
1330:
1325:
1320:
1314:
1312:
1306:
1305:
1303:
1302:
1290:
1278:
1277:
1276:
1264:
1263:
1262:
1257:
1252:
1247:
1235:
1222:
1220:
1216:
1215:
1212:
1211:
1209:
1208:
1199:
1197:
1177:
1176:
1174:
1173:
1161:
1150:
1148:
1133:
1132:
1130:
1129:
1123:
1118:
1113:
1097:
1096:
1090:
1085:
1080:
1064:
1062:
1055:
1054:
1052:
1051:
1039:
1037:Prolymphocytic
1033:
1031:
1024:
1023:
1021:
1020:
1008:
995:
993:
986:
985:
983:
973:
971:
962:
951:
950:
949:
917:
916:
906:
904:
903:
896:
889:
881:
872:
871:
868:
867:
855:
854:
852:
848:
847:
844:
843:
832:
820:
815:
814:
812:
811:Classification
804:
803:External links
801:
798:
797:
756:
729:Cancer Control
715:
655:
620:
585:
549:
503:
457:
436:
400:
399:
397:
394:
385:
382:
373:
370:
327:
324:
303:
300:
262:T-PLL has the
259:
256:
197:
194:
192:
189:
180:
177:
121:
118:
67:
66:
57:
51:
50:
44:
43:
35:
34:
26:
24:
14:
13:
10:
9:
6:
4:
3:
2:
1871:
1860:
1857:
1856:
1854:
1839:
1836:
1834:
1831:
1829:
1826:
1824:
1821:
1819:
1816:
1815:
1813:
1809:
1803:
1800:
1796:
1793:
1791:
1788:
1787:
1786:
1783:
1782:
1780:
1778:
1774:
1764:
1761:
1759:
1756:
1753:
1750:
1748:
1744:
1741:
1740:
1738:
1736:
1735:Lymphocytosis
1732:
1726:
1723:
1722:
1720:
1714:
1704:
1701:
1698:
1694:
1690:
1689:
1685:
1684:
1682:
1678:
1672:
1669:
1667:
1664:
1663:
1661:
1658:
1652:
1648:
1637:
1633:
1632:
1628:
1627:
1625:
1621:
1615:
1612:
1609:
1605:
1602:
1600:
1597:
1595:
1592:
1590:
1589:Hepatosplenic
1587:
1586:
1584:
1582:
1576:
1566:
1563:
1561:
1558:
1556:
1552:
1549:
1548:
1545:
1542:
1540:
1537:
1535:
1531:
1528:
1527:
1525:
1521:
1515:
1512:
1511:
1510:
1509:
1506:
1500:
1497:
1495:
1492:
1490:
1487:
1484:
1483:
1481:
1479:
1475:
1472:
1470:
1466:
1459:
1456:
1454:
1450:
1449:
1445:
1444:
1440:
1436:
1435:
1434:prolymphocyte
1431:
1430:
1427:
1423:
1419:
1416:
1414:
1406:
1403:
1398:
1395:
1393:
1390:
1389:
1388:
1382:
1377:
1372:
1368:
1365:
1363:
1359:
1349:
1346:
1344:
1343:Plasmacytosis
1341:
1339:
1336:
1334:
1331:
1329:
1326:
1324:
1321:
1319:
1316:
1315:
1313:
1311:
1307:
1300:
1299:MALT lymphoma
1296:
1295:
1291:
1288:
1284:
1283:
1279:
1275:
1272:
1271:
1270:
1269:
1265:
1261:
1258:
1256:
1253:
1251:
1248:
1246:
1243:
1242:
1241:
1240:
1236:
1233:
1229:
1228:
1224:
1223:
1221:
1217:
1207:
1206:
1201:
1200:
1198:
1195:
1191:
1186:
1182:
1178:
1171:
1167:
1166:
1162:
1159:
1155:
1152:
1151:
1149:
1146:
1142:
1138:
1134:
1127:
1124:
1122:
1119:
1117:
1114:
1112:
1108:
1107:
1103:
1102:marginal zone
1099:
1098:
1094:
1091:
1089:
1086:
1084:
1081:
1079:
1075:
1074:
1070:
1066:
1065:
1063:
1060:
1056:
1049:
1045:
1044:
1040:
1038:
1035:
1034:
1032:
1029:
1025:
1018:
1014:
1013:
1009:
1006:
1002:
1001:
997:
996:
994:
991:
987:
981:
977:
974:
972:
970:
966:
963:
955:
952:
947:
944:
943:
942:
936:
931:
926:
922:
918:
913:
909:
902:
897:
895:
890:
888:
883:
882:
879:
866:
862:
861:
857:
856:
853:
849:
842:
838:
837:
833:
831:
827:
826:
822:
821:
818:
813:
809:
802:
793:
789:
784:
779:
776:(3): 456–64.
775:
771:
767:
760:
757:
752:
748:
743:
738:
734:
730:
726:
719:
716:
711:
707:
703:
699:
694:
689:
686:(6): 1721–6.
685:
681:
677:
670:
668:
666:
664:
662:
660:
656:
651:
647:
643:
639:
636:(2): 128–32.
635:
631:
624:
621:
616:
612:
608:
604:
600:
596:
589:
586:
581:
577:
573:
569:
565:
561:
553:
550:
545:
541:
537:
533:
529:
525:
522:(1): 111–24.
521:
517:
510:
508:
504:
499:
495:
490:
485:
481:
477:
473:
466:
464:
462:
458:
453:
447:
439:
437:92-832-2411-6
433:
429:
428:
420:
418:
416:
414:
412:
410:
408:
406:
402:
395:
393:
391:
383:
381:
379:
371:
369:
367:
362:
359:
355:
351:
349:
345:
341:
337:
331:
325:
323:
321:
317:
312:
310:
309:chromosome 14
301:
299:
297:
293:
289:
285:
281:
277:
273:
269:
265:
257:
255:
253:
249:
245:
241:
237:
233:
228:
226:
222:
218:
214:
211:
207:
203:
195:
190:
188:
186:
178:
176:
174:
170:
169:immunoglobins
166:
162:
158:
154:
150:
146:
142:
138:
133:
131:
128:, widespread
127:
119:
117:
116:
112:
108:
104:
100:
96:
92:
88:
84:
80:
77:
73:
65:
61:
58:
56:
52:
49:
48:Prolymphocyte
45:
41:
36:
31:
19:
1686:
1629:
1623:By infection
1504:
1503:
1485:
1446:
1438:
1432:
1410:development/
1338:Plasmacytoma
1292:
1280:
1266:
1237:
1225:
1219:By infection
1202:
1163:
1100:
1067:
1041:
1010:
1000:naive B cell
998:
959:development/
858:
834:
823:
773:
769:
759:
735:(1): 19–24.
732:
728:
718:
683:
679:
633:
629:
623:
601:(2): 110–6.
598:
594:
588:
563:
559:
552:
519:
515:
479:
475:
426:
387:
384:Epidemiology
375:
363:
352:
346:, including
340:chlorambucil
332:
329:
316:chromosome 8
313:
305:
261:
229:
204:with single
199:
182:
173:paraproteins
134:
123:
114:
110:
106:
74:is a mature
71:
70:
1505:aggressive:
1478:MF+variants
1017:Mantle cell
1012:mantle zone
378:alemtuzumab
354:Alemtuzumab
202:lymphocytes
141:bone marrow
137:lymph nodes
91:lymph nodes
87:bone marrow
1581:peripheral
1078:Follicular
908:Leukaemias
566:(1): 1–9.
396:References
392:leukemia.
268:neoplastic
248:paracortex
244:lymph node
240:white pulp
210:basophilic
196:Morphology
187:) T-cell.
60:Hematology
1716:Lymphoid+
1486:indolent:
1469:Cutaneous
1310:Cutaneous
1088:GCB DLBCL
1083:Burkitt's
912:lymphomas
446:cite book
372:Prognosis
326:Treatment
320:trisomy 8
213:cytoplasm
191:Diagnosis
175:present.
161:platelets
55:Specialty
1853:Category
1823:leukemia
1381:leukemia
1376:lymphoma
935:leukemia
930:lymphoma
860:Orphanet
792:15716243
751:10761013
710:26664911
702:11535503
650:11063795
544:22030549
236:red pulp
223:seen in
206:nucleoli
79:leukemia
64:oncology
1811:General
1718:myeloid
1680:T or NK
1651:NK cell
1005:CLL/SLL
841:D015461
830:M9834/3
615:9614908
580:1913594
536:3489482
498:1742486
1655:(most
1631:HTLV-1
1523:Non-MF
1412:marker
1385:(most
1371:T cell
1043:CD11c+
961:marker
939:(most
925:B cell
790:
749:
708:
700:
648:
613:
578:
542:
534:
496:
434:
390:T cell
278:, and
252:dermis
242:, and
232:spleen
217:nuclei
185:thymic
179:Causes
165:HTLV-1
151:, and
145:spleen
113:, and
101:, and
99:spleen
76:T-cell
1578:Other
1448:CD30+
1194:CD138
1165:CD20+
1059:CD79a
865:86871
825:ICD-O
706:S2CID
680:Blood
540:S2CID
476:Blood
149:liver
95:liver
83:blood
1657:CD56
1551:CD30
1530:CD30
1418:TdT+
1362:T/NK
1227:KSHV
1203:see
1190:CD38
1181:PCDs
1145:CD30
1141:CD15
1116:MALT
1028:CD22
969:TdT+
946:CD20
941:CD19
836:MeSH
788:PMID
747:PMID
698:PMID
646:PMID
611:PMID
576:PMID
532:PMID
494:PMID
452:link
432:ISBN
288:CD1a
286:and
238:and
208:and
159:and
153:skin
103:skin
1688:EBV
1553:+:
1532:-:
1422:ALL
1397:CD8
1392:CD4
1387:CD3
1282:HIV
1268:HCV
1239:EBV
1143:+,
990:CD5
976:ALL
778:doi
774:123
737:doi
688:doi
638:doi
634:121
603:doi
599:103
568:doi
524:doi
484:doi
296:CD8
292:CD4
284:TdT
280:CD7
276:CD3
272:CD2
1855::
1420::
1408:By
1196:+)
1192:+/
1185:PP
1147:+)
1137:RS
957:By
910:,
863::
839::
828::
786:.
772:.
768:.
745:.
731:.
727:.
704:.
696:.
684:98
682:.
678:.
658:^
644:.
632:.
609:.
597:.
574:.
564:55
562:.
538:.
530:.
520:64
518:.
506:^
492:.
480:78
478:.
474:.
460:^
448:}}
444:{{
404:^
322:.
294:+/
274:,
147:,
143:,
139:,
109:,
97:,
93:,
89:,
85:,
62:,
1754:)
1745:(
1699:)
1695:/
1691:(
1659:)
1653:/
1638:)
1634:(
1610:)
1606:(
1460:)
1451:(
1441:)
1437:(
1428:)
1424:(
1399:)
1383:)
1378:,
1374:(
1301:)
1297:(
1289:)
1285:(
1234:)
1230:(
1188:(
1183:/
1172:)
1168:(
1160:)
1156:(
1139:(
1128:)
1109:(
1104:/
1095:)
1076:(
1071:/
1061:+
1050:)
1046:(
1030:+
1019:)
1015:(
1007:)
1003:(
992:+
982:)
978:(
948:)
937:)
932:,
928:(
900:e
893:t
886:v
817:D
794:.
780::
753:.
739::
733:5
712:.
690::
652:.
640::
617:.
605::
582:.
570::
546:.
526::
500:.
486::
454:)
440:.
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
